Navigation Links
Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer
Date:5/21/2013

BURLINGTON, Mass., May 21, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the effect of an emerging agent on key efficacy endpoints, including overall survival and time to disease progression, has the most influence over surveyed U.S. and European oncologists' prescribing decisions for advanced/metastatic hormone-receptor (HR-) positive, HER2-negative breast cancer. The two novel emerging therapies palbociclib (Pfizer's PD-0332991) and buparlisib (Novartis's BKM-120), both in combination with currently available hormonal therapies, are set to offer efficacy advantages over currently available agents used to treat this patient population.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The Decision Base 2013 report entitled Breast Cancer (Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic): What Attributes will Distinguish Emerging Therapies in the Eyes of Oncologists and Payers?, finds that surveyed U.S. oncologists would prescribe palbociclib to 50 percent of their first-line advanced/metastatic HR-positive, HER2-negative breast cancer patients.

The report also finds that surveyed managed care organization (MCO) pharmacy directors are particularly receptive to novel therapies that offer an improvement in overall response rate (ORR) in this patient population. However, while several emerging therapies hold promise, Decision Resources does not expect any will match the clinical improvement in ORR over current therapies that surveyed U.S. payers indicated would be necessary for widespread inclusion on MCO formularies.

"This population represents a large and therefore potentially lucrative market segment for drug devel
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Next Generation Pharmaceutical Manufacturing Summit Pushes the Envelope of Thought-Leadership at its September Summit in London
2. Avanir Pharmaceuticals Receives Positive CHMP Opinion for Approval of NUEDEXTA in Europe
3. Ludlow Research Issues Opinion on PMBS Based on Low Market Cap Valuation
4. For Osteoporosis and Osteopenia, Clinical Data and Thought Leaders Opinions Indicate that AMG-785/CDP-7851 and Odanacatib Have Advantages Over Alendronate
5. In Pretreated Advanced Renal Cell Carcinoma, Thought Leaders Opinions and Clinical Data Indicate that Tivopath Has Efficacy and Tolerability Advantages Over Currently Used Therapies
6. Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union
7. Active Lifes BioDent Reference Point Indenter Validated in Study Published by Osteoporosis Medical Opinion Leaders
8. Albireo Receives Positive Opinion for Orphan Drug Designation for A4250 for Severe Liver Diseases
9. Hyland Software Forms Multi-Disciplinary Clinical Leadership Team to Augment Healthcare Solutions
10. Claret Medical, Inc. Announces Publication of the First Clinical Research on the Frequency and Composition of Embolic Debris Captured during TAVR
11. A*STAR and Cytos Bring Singapores First Influenza Vaccine to Clinical Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 Revenue and earnings above the ... and development In the past 2013/14 fiscal year ... percent to EUR 4.287 billion (last year: EUR 4.190 billion) ... to EUR 360 million. "Overall, 2013/14 was a successful fiscal ... , President and CEO of Carl Zeiss AG. "Thanks to ...
(Date:12/17/2014)... , Dec. 17, 2014 With advancements ... the MRI market is seeing new growth, according ... MRI scans account for the majority of market ... resolution of images, which are creating opportunities for more ... market is growing at a rate of 4%, ...
(Date:12/17/2014)... , Dec. 17, 2014  ImmunoCellular Therapeutics, Ltd. ... Patent and Trademark Office (USPTO) has issued a ... dendritic cell-based immunotherapeutic vaccine targeting six tumor antigens ... of US Patent No. 8,871,211, which issued October ... by administering a dendritic cell composition comprising peptide ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
(Date:12/20/2014)... 2014 BambooIndustry.com is a professional company ... The business has recently shown its new engineered bamboo ... its bamboo flooring models. , BambooIndustry.com’s customers come from ... and more. According to the CEO of the company, ... fast in the past few years, and the demand ...
(Date:12/20/2014)... Weddingshe.com has recently announced its new collection ... of special occasion dresses for the coming new year. ... occasion dresses for global women. Now, all the models ... to 80% off. Among the new items, the model ... Dress) is very popular. What’s more, Weddingshe.com also provides ...
(Date:12/20/2014)... 2014 DePuy Pinnacle hip lawsuits ... of the artificial hip system was defectively designed ... courts, Bernstein Liebhard LLP reports. According to an ... Court on December 2nd, counsel in 10 DePuy ... plaintiffs on November 19, 2014, with depositions to ...
(Date:12/20/2014)... Recently, VogueQueen.com, a leading wedding dress ... Sale Online for 2015. Great discounts are now ... old consumers can get a discount, up to 80% ... website before January 30, 2015. , VogueQueen.com has recently ... a prom dress promotion. Many customers worldwide like VogueQueen’s ...
(Date:12/20/2014)... 2014 As Risperdal lawsuits ( ... U.S. courts, Bernstein Liebhard LLP notes the publication ... treated with the medication may experience elevated levels ... and lactation. The study, which appears in International ... who began treatment with risperidone, an antipsychotic medication ...
Breaking Medicine News(10 mins):Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2Health News:Tons of New-in Winter Sweet 16 Dresses from Weddingshe Online Now 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:VogueQueen Big Sale Online For The Coming 2015 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4
... for new mothers, according to a study in the ... researcher Dr. Robert Whitaker. , While smoking and ... also affect the health of her child, Whitaker said. ... smoking include sudden infant death, asthma, ear infections and ...
... awareness of Molluscum Contagiosum, CHARLES TOWN, W.V., ... RBRM) a provider of treatment for diabetic,peripheral neuropathy ... the month of October 2007; increase is 12% ... "As public awareness of the dangers related ...
... YORK, Nov. 26 /Xinhua-PRNewswire-FirstCall/ -- itLinkz Group, Inc.,("ILKZ") ... beginning of,trading today, November 26, 2007, the Company ... Inc." and began trading under its new,symbol (OTC ... a,1:28 reverse split of its outstanding common shares ...
... Giesing, Chief Scientific,Officer and Terry Nida, Chief Operating ... (http://www.urigen.com ) will be featured in an,exclusive ... 27 at 10:30,a.m. EST. The interview will be ... EST on,November 27., The interview will cover ...
... 26, 2007) Rutgers College of Nursing faculty member ... of the Rutgers-Newark Provosts Award for Community Engagement in ... significance based in whole or in part on data ... Diner, Rutgers-Newark provost, established the Provosts Awards for Community ...
... technology allows medical professionals to instantly ... access and manipulate ... a global leader in,software-driven systems for targeted, less-invasive medical ... at the,Annual Meeting of the Radiological Society of North ...
Cached Medicine News:Health News:Smoking and depression often co-occur in new mothers 2Health News:ReBuilder Medical Technologies, Inc. Announces Record Sales Month 2Health News:itLinkz Group, Inc. Changes Name to China YCT International Group, Inc. and Effects Reverse Stock Split 2Health News:WallSt.net Announces Upcoming Interview with CSO and COO of Urigen Pharmaceuticals 2Health News:Rutgers College of Nursing faculty member Rachel Jones awarded Rutgers-Newark Provost Award 2Health News:Digital Lightbox(C) Unlocks New Possibilities in Collaborative Patient Treatment 2Health News:Digital Lightbox(C) Unlocks New Possibilities in Collaborative Patient Treatment 3
... to facilitate an arthrodesis, either by an ... cages allowing radicular compression by restoring the ... of the foramina, which in turn enhances ... major lumbar instabilities.,CC cages are made of ...
... The PACHETT 3 uses the exact enhanced ... the DGH pachymeters used exclusively by the ... built into the software. The new backlit ... running average, standard deviation and IOP correction ...
... Already, the most advanced motor driven ... easier and faster to learn and operate. ... maintaining accuracy and precision. Our software makes ... easy transition from manual instruments or other ...
The Medmont C100 Colour Vision Tester is an electronic colour vision screening device which is used to rapidly detect red/green colour vision deficiencies. Its high sensitivity provides a positive in...
Medicine Products: